BRAF and cancer: Although dramatic decreases in the cancer cell metabolism gene signature ensue with combined BRAF/MEK inhibition, indicative of an overall low metabolic activity in MRD (19), this metabolic signature was decreased to a significantly lesser extent in the CD36+ cells, compared with the CD36– subpopulation (Figure 4C).